Certain Myasthenia Gravis Patients May Need More Time to Respond to Efgartigimod
(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to show efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, according to open-label data from...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.